Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2479MR)

This product GTTS-WQ2479MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000885.6; NM_000889.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695
UniProt ID P13612; P26010
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2479MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14001MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ3325MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ3495MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ10019MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ14073MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ10702MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ10413MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ7698MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW